期刊文献+

乳腺梭形细胞/肉瘤样化生性癌临床病理和免疫表型分析 被引量:11

Spindle cell/sarcomatoid metaplastic carcinoma of breast:a clinicopathologic and immunohistochemical analysis
下载PDF
导出
摘要 目的探讨以梭形细胞/肉瘤样成分为主的乳腺化生性癌(metaplastic breast carcinoma with dominant spindle cell/sarcoma-toid component,MBCSC)的临床病理及免疫表型特点。方法复习15例MBCSC的临床病理资料,并对其中12例肿瘤进行免疫组化染色(抗体包括上皮标记、肌上皮标记和肿瘤标记物)。同时就腋淋巴结状态,ER、PR和Her2的表达与浸润性导管癌做简要比较。结果本组MBCSC患者平均年龄41岁,均因发现乳腺包块就诊。多数肿瘤呈界限清楚的结节状。镜下8例肿瘤完全由梭形/肉瘤样细胞构成,6例以梭形/肉瘤样细胞为主伴少量浸润性导管癌(invasive ductal carcinoma IDC)成分,1例伴少量导管原位癌。肿瘤显示中-高级别组织学改变。11/12例(91.7%)MBCSC的梭形细胞/肉瘤样成分至少表达一种上皮标记,全部病例均至少表达一种肌上皮标记。本组MBCSC的腋淋巴结转移率和ER、PR、Her2的表达均低于对照组。结论 MBCSC在独特的组织病理学基础上呈现出肌上皮分化,其生物学特性如腋淋巴结状态和肿瘤标记物的表达与浸润性导管癌有所不同,提示其可以作为独立的病理亚型。系列上皮和肌上皮标记的免疫组化染色有助于MBCSC的病理诊断。 Purpose To study the clinicopathologic and immunohistochemical features of metaplastic breast carcinoma with dominant spindle cell/sarcomatoid component(MBCSC).Methods Clinicopathologic data of 15 cases of MBCSC were analyzed.Immunohistochemical staining were performed in 12 cases(including epithelial markers,myoepithelial and tumor markers).Differences in axillary lymph node metastases,and the expression of ER,PR,Her2 were assessed between MBCSC and invasive ductal carcinoma(IDC).Results The mean age of the patients was 41 year-old.The main complain of all patients was noting a breast lump.Grossly,most tumors were well-circumscribed nodules.8 cases of tumors contained almost pure spindle cell,6 cases of tumors contained mainly spindle cell /sarcomatoid with a small area of IDC and 1 case of tumor with a little DCIS component.The tumors displayed moderate-high grade of histological morphology.11/12 cases(91.7%) of spindle cell/sarcomatoid components were positive for at least one epithelial markers.All cases of spindle cell expressed at least one or more than one myoepithelial markers.The rate of axillary lymph node metastases and the expression of ER,PR,Her2 were lower in case group than that in control group.Conclusions MBCSC exhibits characteristically histopathologic morphology and myoepithelial differentiation,with the biologic features such as the axillary lymph node metastases and the expression of tumor markers were different from IDC,suggesting an independent pathologic subtype.Immunohistochemical staining of series of epithelial and myoepithelial markers could contribute to the pathologic diagnosis.
出处 《临床与实验病理学杂志》 CAS CSCD 北大核心 2010年第3期270-274,共5页 Chinese Journal of Clinical and Experimental Pathology
关键词 乳腺肿瘤 化生性癌 梭形细胞 肉瘤样 免疫组织化学 breast neoplasms mataplastic carcinoma spindle cell sarcomatoid immunohistochemistry
  • 相关文献

参考文献4

二级参考文献40

  • 1丁华野,皋岚湘.乳腺肌纤维母细胞增生及肿瘤性病变[J].中华病理学杂志,2004,33(4):378-381. 被引量:18
  • 2<乳腺癌HER2检测指南>编写组,霍临明.乳腺癌HER2检测指南[J].中华病理学杂志,2006,35(10):631-633. 被引量:164
  • 3Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol, 2007,25 ( 33 ) : 5287-5312.
  • 4Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol,2007,25( 1 ) :118-145.
  • 5Hanna WM, Kwok K. Chromogenic in-situ hybridization: a viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithm. Mod Pathol,2006,19(4) :481-487.
  • 6Gong Y, Sweet W, Duh YJ, et al. Chromogenic in situ hybridization is a reliable method for detecting HER2 gene status in breast cancer: a multicenter study using conventional scoring criteria and the new ASCO/CAP recommendations. Am J Clin Pathol,2009,131 (4) :490-497.
  • 7Dietel M, Ellis IO, Hofler H, et al. Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists. Virchows Arch ,2007,451 ( 1 ) : 19-25.
  • 8Pedersen M, Rasmussen BB. The correlation between dual-color chromogenic in situ hybridization and fluorescence in situ hybridization in assessing HER2 gene amplification in breast cancer. Diagn Mol Pathol,2009,18 (2) :96-102.
  • 9Yaziji H, Gown AM. Accuracy and precision in HER2/neu testing in breast cancer: are we there yet? Hum Pathol, 2004, 35 (2): 143-146.
  • 10Sauter G, Lee J, Bartlett JM, et al. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologie considerations. J Clin Oncol, 2009,27 (8) : 1323- 1333.

共引文献225

同被引文献59

引证文献11

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部